Results 201 to 210 of about 181,087 (306)

Cytomegalovirus Infection After Chimeric Antigen Receptor T-Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. [PDF]

Transpl Infect Dis
Han J, Lim SY, Hyung J, Cho H, Yoon DH, Kim SH.   +5 more
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source

Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma. [PDF]

World J Gastroenterol
Watanabe T.
europepmc   +1 more source

Marine silicon for biomedical sustainability

BMEMat, EarlyView.
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han, Zhibo Yang, Wei Xia, Chengtie Wu   +3 more
wiley   +1 more source

Glutamate metabotropic receptor 4 in breast cancer: a potential and specific target for chimeric antigen receptor therapy. [PDF]

Front Oncol
Xu Y, Hayierhan A, Chen Z, Ma Y, Zhang W, Xu C, Mei R, Zhou X, Zhu Y, Sun P, Wu J.   +10 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Commentary: is trogocytosis relevant for chimeric antigen receptor-T cells? [PDF]

Oncologist
Toolabi B, Whiteheart SW, Munker R.
europepmc   +1 more source

Nanogel‐Mediated Immunotherapy to Tackle Cancer and Inflammatory Diseases

ChemistryEurope, EarlyView.
Nanogels formed through self‐assembly, microemulsion, or precipitation polymerization method enable precise delivery of immunotherapeutic factors and immune cell targeting, thus effectively modulating immune responses. This review highlights recent advances in stimuli‐responsive nanogel design, underlying mechanisms, and their potentials to tackle ...
Ziwen Zhang, Jinxia Wang, Guang‐Zhi Jin, István Bányai, Dzmitry Shcharbin, Ivan Stoikov, Mingwu Shen, Xiangyang Shi   +7 more
wiley   +1 more source

IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer. [PDF]

Commun Biol
Chen Y, Zhu X, Chen Y, Yang Z, Shen Z, Chen M, Liu C, Zhou Y, Wang H, Zhu M, Qiu J, Huang J, Han X, Wei W, Ruilin L, Hong W, Tu J.   +16 more
europepmc   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source